Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedSep 23, 2015Sodium Tetradecyl Sulfate 5% InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1635-2015Class IITerminatedSep 23, 2015Sodium Ascorbate 500 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1634-2015Class IITerminatedSep 23, 2015Sermorelin 300 mcg/ml + GHRP-2 300 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1633-2015Class IITerminatedSep 23, 2015Sermorelin 1000mcg/GHRP6 1000/GHRP2 1000 ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1632-2015Class IITerminatedSep 23, 2015Sermorelin/GHRP6 1000/1000 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1631-2015Class IITerminatedSep 23, 2015Sermorelin/GHRP2 1000/1000 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1630-2015Class IITerminatedSep 23, 2015Sermorelin 1000 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1629-2015Class IITerminatedSep 23, 2015Selenium 200 mcg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1628-2015Class IITerminatedSep 23, 2015Pyridoxine Hydrochloride 100 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1627-2015Class IITerminatedSep 23, 2015Progesterone 100 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1626-2015Class IITerminatedSep 23, 2015Polidocanol 5% InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1625-2015Class IITerminatedSep 23, 2015Polidocanol 1% InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1624-2015Class IITerminatedSep 23, 2015Phosphatidylcholine 0.1% Sodium Deoxycholate 0.089% InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1623-2015Class IITerminatedSep 23, 2015PGE 80 (Alprostadil) 80 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1622-2015Class IITerminatedSep 23, 2015PGE 40 (Alprostadil) 40 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1621-2015Class IITerminatedSep 23, 2015PGE 150Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1620-2015Class IITerminatedSep 23, 2015Oxytocin 100 units/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1619-2015Class IITerminatedSep 23, 2015Neomycin + Polymyxin B+ Bacitracin Ophthalmic OintmentLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1618-2015Class IITerminatedSep 23, 2015Nandrolone Decanoate 250 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1617-2015Class IITerminatedSep 23, 2015Nandrolone Decanoate 200 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1616-2015Class IITerminatedSep 23, 2015Morphine 70 mg/ml + Clonidine 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1615-2015Class IITerminatedSep 23, 2015Morphine 70 mg/ml + Bupivacaine 40 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1614-2015Class IITerminatedSep 23, 2015Morphine 64 mg/ml + Bupivacaine 10 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1613-2015Class IITerminatedSep 23, 2015Morphine 60 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1612-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml +Fentanyl 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1611-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Clonidine 200 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1610-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Clonidine 100 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1609-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Bupivacaine 2.5 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1608-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1607-2015Class IITerminatedSep 23, 2015Morphine 45 mg/ml + Bupivacaine 40 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1606-2015Class IITerminatedSep 23, 2015Morphine 45 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1605-2015Class IITerminatedSep 23, 2015Morphine 42 mg/ml + Bupivacaine 8 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1604-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml + Fentanyl 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1603-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml + Clonidine 500 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1602-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml + Bupivacaine 8 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1601-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml + Bupivacaine 16 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1600-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1599-2015Class IITerminatedSep 23, 2015Morphine 36 mg/ml + Bupivacaine 40 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1598-2015Class IITerminatedSep 23, 2015Morphine 35 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1597-2015Class IITerminatedSep 23, 2015Morphine 33 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1596-2015

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.